Leupeptin, hemisulfate (Microbial)

CAS No. : 103476-89-7

Leupeptin, hemisulfate (Microbial),103476-89-7
Product Details
For research use only. Not Intended for Therapeutic Use!
Cat No:I000208
Synonyms:Leupeptin hemisulfate; 2-acetamido-N-(1-((5-((diaminomethylene)amino)-1-oxopentan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)-4-methylpentanamide
Molecular Formula:C₂₀H₃₈N₆O₄.1/2 H₂SO₄.H₂O
Molecular Weight:493.61
Target:Serine Protease
Price:Get quote
We would like to match the lowest price on market if possible.

Your information is safe with us.


Appearance:A crystalline solid
Cat No:I000208
Cas No:103476-89-7
Product-Name:Leupeptin, hemisulfate (Microbial)
MDL No:MFCD00037012

Leupeptin hemisulfate(cas 103476-89-7) is a reversible, competitive serine/cysteine protease inhibitor, which has been shown to inhibit cathepsin B (Ki = 6 nM), calpain (Ki = 10 nM), trypsin (Ki = 35 nM), plasmin (Ki = 3.4 μM), and kallikrein (Ki = 19 μM), and has no effect against chymotrypsin, elastase, renin, or pepsin. Leupeptin has been shown to be protective of auditory hair cells exposed to disruptive noise or ototoxic aminoglycoside-type antibiotics.

1. J Mol Biol. 2006 Mar 17;357(1):195-209. Epub 2005 Dec 28.
X-ray structures of free and leupeptin-complexed human alphaI-tryptase mutants: indication for an alpha-->beta-tryptase transition.
Rohr KB(1), Selwood T, Marquardt U, Huber R, Schechter NM, Bode W, Than ME.
Author information:
(1)Max-Planck-Institut für Biochemie, Abteilung Strukturforschung, Am Klopferspitz 18, 82152 Martinsried, Germany.
Tryptases alpha and beta are trypsin-like serine proteinases expressed in large amounts by mast cells. Beta-tryptase is a tetramer that has enzymatic activity, but requires heparin binding to maintain functional and structural stability, whereas alpha-tryptase has little, if any, enzymatic activity but is a stable tetramer in the absence of heparin. As shown previously, these differences can be mainly attributed to the different conformations of the 214-220 segment. Interestingly, the replacement of Asp216 by Gly, which is present in beta-tryptase, results in enzymatically active but less stable alpha-tryptase mutants. We have solved the crystal structures of both the single (D216G) and the double (K192Q/D216G) mutant forms of recombinant human alphaI-tryptase in complex with the peptide inhibitor leupeptin, as well as the structure of the non-inhibited single mutant. The inhibited mutants exhibited an open functional substrate binding site, while in the absence of an inhibitor, the open (beta-tryptase-like) and the closed (alpha-tryptase-like) conformations were present simultaneously. This shows that both forms are in a two-state equilibrium, which is influenced by the residues in the vicinity of the active site and by inhibitor/substrate binding. Novel insights regarding the observed stability differences as well as a potential proteolytic activity of wild-type alpha-tryptase, which may possess a cryptic active site, are discussed.
2. Med Sci Monit. 2004 Jan;10(1):BR4-10.
Protease inhibitor leupeptin attenuates myocardial stunning in rat heart.
Rudziński T(1), Mussur M, Gwiazda Z, Mussur M.
Author information:
(1)Department of Cardiosurgery, Institute of Cardiology, Medical University of Łodź, Poland.
BACKGROUND: In order to test the hypothesis that cardiac protein degradation contributes to the pathogenesis of myocardial stunning, the effect of protease inhibitor leupeptin on the postischemic hemodynamics and metabolic functioning was measured in isolated rat hearts.
MATERIAL/METHODS: Isolated rat hearts were perfused in Langendorff mode in the presence or absence of leupeptin (10 Kg/ml for 10 min.), and then subjected to 20 min. of normothermic ischemia and 30 min. of reperfusion. Aortic pressure, cardiac output, coronary flow (CF), global oxygen consumption (MVO2), carbon dioxide and [H+] release, and [Ca2+] uptake were investigated. RESULTS: Hearts pretreated with leupeptin exhibited better postischemic return of systolic, diastolic and developed aortic pressure and faster return of CF to preischemic values during reperfusion. MVO2 and CO2 release were lower in this group in the 10th and 15th min. of reperfusion and [Ca2+] uptake higher in the 5th and 15th min. of reperfusion
CONCLUSIONS: Leupeptin protects the heart from myocardial stunning, which is consistent with the idea that proteases contribute to the pathogenesis of this phenomenon.
3. Neuroscience. 2004;125(2):427-39.
Inhibition of calpains, by treatment with leupeptin, improves motoneuron survival and muscle function in models of motoneuron degeneration.
Kieran D(1), Greensmith L.
Author information:
(1)The Graham Watts Laboratories, Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, University College London, Queen Square, London WC1N 3BG, UK.
The effect of treatment with leupeptin, a calpain inhibitor, on motoneuron survival and muscle function was examined in in vitro and in vivo models of motoneuron degeneration. Exposure of primary rat motoneurons to alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) is an established in vitro model of excitotoxic motoneuron death. Here we show that leupeptin treatment improved motoneuron survival following exposure to AMPA (50 microM). Application of leupeptin (100 microM) to AMPA treated cultures rescued many motoneurons so that 74% (+/-3.4 S.E.M., n=5) survived compared with only 49% (+/-2.4 S.E.M., n=5) in untreated cultures. The effect of treatment with leupeptin on motoneuron survival and muscle function was also examined in vivo. In 3 day-old rats, the sciatic nerve was crushed and at the time of injury, a silicon implant containing leupeptin was inserted onto the lumbar spinal cord. The effect on long-term motoneuron survival and muscle function was assessed 12 weeks after injury. The results showed that there was long-term improvement in motoneuron survival in the leupeptin treated group. Thus, in untreated animals 12 weeks after nerve crush only 30% (+/-2.8. S.E.M., n=3) of sciatic motoneurons survived compared with 43% (+/-1.5 S.E.M., n=3) in the leupeptin-treated group. This improvement in motoneuron survival was reflected in a significant improvement in muscle function in the leupeptin-treated group. For example in the soleus muscle of treated rats 20.8 (+/-1.40 S.E.M., n=5) motor units survived compared with only 14.6 (+/-1.21 S.E.M., n=5) in untreated animals. Thus, treatment with leupeptin, a calpain inhibitor, rescues motoneurons from cell death and improves muscle function following nerve injury.
Related Products
  • CAS No. :313649-08-0
    Product Name:

    UCF 101

    Cat No: I012039 View details
  • CAS No. :217099-44-0
    Product Name:

    BCX 1470 methanesulfonate

    Cat No: I002660 View details
  • CAS No. :217099-43-9
    Product Name:

    BCX 1470

    Cat No: I002659 View details
  • CAS No. :649748-23-2
    Product Name:

    PPACKII (trifluoroacetate salt)

    Cat No: I011793 View details